The CSL (ASX:CSL) share price has struggled to gain traction in 2022. Does that make it cheap?

Are CSL shares cheap with it being down over 10% this year?

| More on:
A compass with the word opportunities is shown in black and blue representing a broker upgrade on the EML share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price hasn’t been a strong performer in 2022
  • CSL shares are down 13% since the start of the year, does this mean it’s now cheap?
  • Some investors think that CSL is an opportunity

The CSL Limited (ASX: CSL) share price has struggled since the start of 2022. It's down over 13%. Does that mean that the ASX healthcare share is cheap?

It's now lower than it was at the bottom of the COVID-19 crash.

What's going on with the CSL share price?

My colleague Tony Yoo has quoted the fund manager Jun Bei Liu from investment manager Tribeca.

She said pointed out that healthcare names have underperformed, not because of the war but because they were expensive companies relative to other sectors.

There is also the prospect of much faster interest rate hikes to combat the high level of inflation that the world is seeing.

Billionaire Ray Dalio from investment group Bridgewater Associates once said about interest rates:

It all comes down to interest rates. As an investor, all you're doing is putting up a lump sum payment for a future cash flow.

The CSL share price initially rose after investors got a look at the result, but it has since dropped back.

To be able to call something "cheap", knowing how much profit a business is generating can be useful.

FY22 half-year result

CSL reported a net profit after tax (NPAT) of $1.67 billion for the first six months of FY22, which was down 5% in constant currency terms. However, revenue was up 4% in constant currency terms.

Management said that was strong growth in a number of areas for the business, whilst HPV royalties rebounded strongly (up 134%). Seqirus, the influenza vaccine business, was one of the segments that saw a strong performance with revenue up 17% in constant currency terms.

Ig and albumin sales were limited by constrained plasma collections in FY21.

In FY22, the net profit is expected to be in the range of between $2.15 billion to $2.25 billion at constant currency.

The interim dividend was increased by 8% in Australian dollar terms to A$1.46 per share.

Acquisition

The company also recently announced that it was acquiring Vifor Pharma, a global specialty pharmaceutical company with leadership in renal disease and iron deficiency.

Management said this will represent a meaningful acceleration of its 2030 strategy by further enhancing its focus on therapeutic leadership areas, innovation and sustainable growth.

Is the CSL share price a cheap buy?

When talking about CSL, Resmed CDI (ASX: RMD) and Cochlear Limited (ASX: COH), the fund manager Liu said:

All of them have reported pretty good numbers… And since then the share prices have come off again

All of that together makes these companies absolute standouts. When there's a rebound it is these companies that will be the first ones to move [upwards]. They have pricing power. They can apply faster price increases so that their earnings growth is not going to be impacted. These companies will continue to grow.

Plenty of brokers also think that CSL is a buy, such as Citi, with a price target of $335. Morgans is another broker with a positive outlook – it rates CSL as a buy with a price target of $327.60.

On Citi's numbers, the CSL share price is valued at 30x FY23's estimated earnings.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. and Cochlear Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman stares at a computer with her face just inches from the screen.
Healthcare Shares

ASX IPO watch: Aspiring healthcare stock has attracted former Macquarie CEO to invest

And former federal health minister Greg Hunt is a board director.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 180% in a year, is it too late to buy Pro Medicus shares?

The question lingers.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Pro Medicus share price rockets 13% on biggest ever contract win

Pro Medicus shares are leaping higher on Thursday.

Read more »

A woman with bright yellow hair wearing a brightly patterned blouse reacts to big news that she's reading on her phone.
Earnings Results

Guess which ASX 100 share is sinking despite record results

This healthcare stock had a record half. Here's what drove its growth.

Read more »

A group of men in the office celebrate after winning big.
Healthcare Shares

Is the CSL share price heading to $345? This analyst thinks so

Let's see why one analysts is tipping this high-quality stock to outperform.

Read more »

A young office worker is surrounded by peers who are clapping and congratulating her.
Healthcare Shares

Up 140% in 2024, here's why this ASX 200 healthcare stock is making news again today

It’s yet another positive update for this stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 ASX healthcare shares surging on big news

The ASX healthcare sector is higher on Tuesday and these stocks are among the strongest performers.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The pros and cons of buying CSL shares right now

It’s an interesting time to consider this healthcare giant.

Read more »